Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Becton Dickinson and Company

Abingdon Health PLC ( ($GB:ABDX) ) has provided an announcement. Abingdon Health plc reported significant growth and expansion in its final results...

Abingdon Health Reports Strong Growth and Expansion in FY25 Results

Becton, Dickinson and Co (($BDX)) has held its Q4 earnings call. Read on for the main highlights of the call. Becton, Dickinson and Co. (BD) recent...

BD’s Earnings Call: Strong Growth Amid Challenges

The latest announcement is out from Abingdon Health PLC ( ($GB:ABDX) ). Abingdon Health PLC announced that all resolutions proposed at its General ...

Abingdon Health PLC Secures Shareholder Approval for Fundraising

BCAL Diagnostics Limited ( ($AU:BDX) ) has shared an announcement. BCAL Diagnostics Limited has announced its Annual General Meeting (AGM) for shar...

BCAL Diagnostics Schedules Annual General Meeting for November 2025

The latest update is out from BCAL Diagnostics Limited ( ($AU:BDX) ). BCAL Diagnostics Limited has announced its Annual General Meeting scheduled f...

BCAL Diagnostics Schedules Annual General Meeting for 2025

Becton, Dickinson and Co (($BDX)) announced an update on their ongoing clinical study. Study Overview: Becton, Dickinson and Co (BDX) is conducting...

BDX’s Innovative Study on BD PosiFlush™ SafeScrub: Market Insights

BCAL Diagnostics Limited ( ($AU:BDX) ) has provided an update. BCAL Diagnostics Limited has announced the quotation of 1,849,750 fully paid ordinar...

Market Cap	$53.26B	P/E Ratio	13.00
52W High	$251.99	52W Low	$162.29
Div Yield	420.0%	Payout Ratio	317.3%
EPS Growth 3Y	-5.3%	52W Position	33.9%
Overall Score	66	Value Score	70
Quality Score	--	Technical Score	63

EPS Current Est	$14.83	EPS Next Est	$15.8
EPS Growth Est	+6.5%	DPS Growth 3Y	4.6%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BDX	$192.72	+1.66%	3.00M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BDX	$192.72	+1.7%	3.00M
3
4
5
6

BDX

BDX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Becton Dickinson and Company Data in Excel

Get Becton Dickinson and Company Data in Excel